Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troriluzole for Methamphetamine Use Disorder
NCT06989853Phase 1Recruiting
- Start
- Aug 2025
- Primary completion
- Feb 2029
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of troriluzole in methamphetamine use disorder (MUD) (3 arms). Primary endpoint: Reinforcing Effects of Methamphetamine at 1 month. Started Aug 2025; status: recruiting.
02
Drugs
troriluzole
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT06989853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989853.